Orofacial Granulomatosis Associated with Crohn's Disease: a Multicentre Case Series. (8th September 2021)

• Record Type: Journal Article
• Authors: Phillips, Frank; Verstockt, Bram; Sladek, Malgorzata; de Boer, Nanne; Katsanos, Konstantinos; Karmiris, Konstantinos; Albshesh, Ahmad; Erikson, Carl; Bergemalm, Daniel; Molnar, Tamas; Ellul, Pierre
• Is Part Of: Journal of Crohn's and colitis. Volume 16:Number 3(2022)
• Page Start: 430
• Page End: 435
• Publication Date: 2021-09-08
• Subjects: Orofacial granulomatosis -- oral Crohn's disease -- inflammatory bowel disease -- Crohn's disease -- ulcerative colitis; Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjab158
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: Orofacial granulomatosis [OFG] is a rare syndrome that may be associated with Crohn's disease [CD]. We aimed to characterise this relationship and the management options in the biologic era. Methods: This multicentre case series was supported by the European Crohn's and Colitis Organisation [ECCO], and performed as part of the Collaborative Network of Exceptionally Rare case reports [CONFER] project. Clinical data were recorded in a standardised collection form. Results: This report includes 28 patients with OFG associated with CD: 14 males (mean age of 32 years, ±12.4 standard deviation [SD]) and 14 females [40.3 years, ±21.0 SD]. Non-oral upper gastrointestinal tract involvement was seen in six cases and perianal disease in 11. The diagnosis of OFG was made before CD diagnosis in two patients, concurrently in eight, and after CD diagnosis in 18. The distribution of OFG involved the lips in 16 cases and buccal mucosa in 18. Pain was present in 25 cases, with impaired swallowing or speaking in six. Remission was achieved in 23 patients, notably with the use of anti-tumour necrosis factors [TNFs] in nine patients, vedolizumab in one, ustekinumab in one, and thalidomide in two. A further five cases were resistant to therapies including anti-TNFs. Conclusions: OFG associated with CD may occur before, concurrently with, or after the diagnosis of CD. Perianal and upper gastrointestinal [UGI] disease are common associations and there is a significant symptom burden in many. Remission can be obtained with a variety of immunosuppressive treatments, including several biologics approved for CD.